Tag: SSY Group

SSY Group Limited (“SSY” or the “Company”; Stock Code: 2005.HK) and its subsidiaries (together, the “Group”) presents the annual results of the Company for the year ended 31 December 2020 (“2020” or “the year”).

During the first half year, the operational activities of various sizes of hospitals and various types of clinics in the PRC were severely disrupted by the epidemic and thus the number of patients substantially decreased.

We continued to be the company with the fastest growth of production and sales volume in the intravenous infusion solutions industry.

During the first half of the year, the Group achieved a revenue of HK$2,326 million, representing an increase of 11.1% compared to the corresponding period of last year, and the gross profit margin increased by 1 percentage point.